In 2023, prostate cancer remains a significant health burden, with an estimated 288 300 new cases and 34 700 deaths in the US.1 For men with a new diagnosis, optimal treatment management depends on a variety of factors related to patients’ age, prostate-specific antigen (PSA) levels, tumor stage, and pathology from standardized multicore biopsy. The gene discussed is KLK3; the disease is Familial prostate cancer.